Cargando…
Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
Levamisole exposure in cocaine users is a well-recognized cause of retiform purpura, a distinctive net-like maculopapular patch. Prolonged exposure to levamisole can lead to a serious systemic syndrome known as levamisole-induced vasculitis, most commonly involving the kidneys and lungs. More recent...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607060/ https://www.ncbi.nlm.nih.gov/pubmed/34807290 http://dx.doi.org/10.1007/s00403-021-02303-1 |
_version_ | 1784602477794951168 |
---|---|
author | Keim, Catherine K. Schwartz, Robert A. Kapila, Rajendra |
author_facet | Keim, Catherine K. Schwartz, Robert A. Kapila, Rajendra |
author_sort | Keim, Catherine K. |
collection | PubMed |
description | Levamisole exposure in cocaine users is a well-recognized cause of retiform purpura, a distinctive net-like maculopapular patch. Prolonged exposure to levamisole can lead to a serious systemic syndrome known as levamisole-induced vasculitis, most commonly involving the kidneys and lungs. More recently, retiform purpura has been observed in patients with the novel coronavirus disease of 2019 (COVID-19). Due to their overlapping dermatologic and systemic manifestations, levamisole-induced and COVID-19-induced retiform purpura may mimic one another in clinical presentation. The possibility that patients may present with one or both syndromes creates a diagnostic challenge. This review of levamisole-induced and COVID-19-induced retiform purpura highlights their corresponding and distinctive features. Additionally, we propose a unique staging system for levamisole-induced retiform purpura that may be valid for future classification of COVID-19-induced retiform purpura. |
format | Online Article Text |
id | pubmed-8607060 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-86070602021-11-22 Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes Keim, Catherine K. Schwartz, Robert A. Kapila, Rajendra Arch Dermatol Res Concise Communications Levamisole exposure in cocaine users is a well-recognized cause of retiform purpura, a distinctive net-like maculopapular patch. Prolonged exposure to levamisole can lead to a serious systemic syndrome known as levamisole-induced vasculitis, most commonly involving the kidneys and lungs. More recently, retiform purpura has been observed in patients with the novel coronavirus disease of 2019 (COVID-19). Due to their overlapping dermatologic and systemic manifestations, levamisole-induced and COVID-19-induced retiform purpura may mimic one another in clinical presentation. The possibility that patients may present with one or both syndromes creates a diagnostic challenge. This review of levamisole-induced and COVID-19-induced retiform purpura highlights their corresponding and distinctive features. Additionally, we propose a unique staging system for levamisole-induced retiform purpura that may be valid for future classification of COVID-19-induced retiform purpura. Springer Berlin Heidelberg 2021-11-22 2023 /pmc/articles/PMC8607060/ /pubmed/34807290 http://dx.doi.org/10.1007/s00403-021-02303-1 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Concise Communications Keim, Catherine K. Schwartz, Robert A. Kapila, Rajendra Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
title | Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
title_full | Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
title_fullStr | Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
title_full_unstemmed | Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
title_short | Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
title_sort | levamisole-induced and covid-19-induced retiform purpura: two overlapping, emerging clinical syndromes |
topic | Concise Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607060/ https://www.ncbi.nlm.nih.gov/pubmed/34807290 http://dx.doi.org/10.1007/s00403-021-02303-1 |
work_keys_str_mv | AT keimcatherinek levamisoleinducedandcovid19inducedretiformpurpuratwooverlappingemergingclinicalsyndromes AT schwartzroberta levamisoleinducedandcovid19inducedretiformpurpuratwooverlappingemergingclinicalsyndromes AT kapilarajendra levamisoleinducedandcovid19inducedretiformpurpuratwooverlappingemergingclinicalsyndromes |